Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,190.00
Bid: 12,210.00
Ask: 12,214.00
Change: 162.00 (1.35%)
Spread: 4.00 (0.033%)
Open: 12,036.00
High: 12,214.00
Low: 12,024.00
Prev. Close: 12,028.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 2-European shares rebound as Brexit trade deal progress overshadows virus worries

Tue, 22nd Dec 2020 10:05

(For a Reuters live blog on U.S., UK and European stock
markets, click LIVE/ or type LIVE/ in a news window)

* Britain-EU rifts over fishing narrow

* U.S. Congress approves $892 bln pandemic aid package

* Tech stocks, banks lead broad-based gains in Europe

* AstraZeneca slips as asthma drug fails in late-stage trial
(Updates to close)

By Susan Mathew

Dec 22 (Reuters) - European shares posted their best day in
six weeks on Tuesday, rebounding from a sharp sell-off as
optimism around Brexit and U.S. stimulus helped to allay worries
of a further hit to the global economy from a new coronavirus
variant in Britain.

The pan-European STOXX 600 index finished up 1.2%
on broad-based gains, recovering from a more than 2% slide in
the previous session, which was also its biggest one-day drop in
nearly two months.

The European Union is giving a "final push" in a bid to
strike a Brexit trade deal with Britain, its chief negotiator
said on Tuesday, with the two sides inching towards agreement on
fishing - a major sticking point - days before the end of
Britain's transition deal since it left the bloc.

"(The progress in fishing) highlights the willingness to
move towards something that will eventually break the current
deadlock," said Joshua Mahony, senior market analyst at online
trading platform IG.

Helping London's blue-chip index reverse early
losses, data showed Britain's economic recovery from its
coronavirus crash was quicker than previously thought in the
third quarter. The index closed 0.6% higher, breaking a
three-day losing streak.

The losses were triggered by the emergence of a
fast-spreading new coronavirus variant in Britain, which has
forced wider lockdowns there and led countries around the world
to close their borders to the UK. The EU on Tuesday recommended
rolling back border closures to allow freight to resume.

"The COVID-led economic isolation of the UK (is) serving to
provide a heavy dose of reality of the kind of disruption that
could come if negotiators fail to agree a (Brexit trade) deal by
year-end," Mahony said.

Technology stocks and Brexit-sensitive banks
led the rebound in Europe, while materials stocks lagged
as they tracked a decline in underlying commodity prices.

Meanwhile, U.S. President Donald Trump on Tuesday signed a
stopgap measure to fund U.S. agencies for another week after
Congress passed a long awaited $892 billion COVID-19 aid package
overnight.

AstraZeneca was the biggest weight on the pan-region
index, down 1.5% after its experimental asthma drug developed
with U.S partner Amgen failed to meet the main goal of
a late-stage trial.
(Additional reporting by Supriya R in Bengaluru; Editing by
Anil D'Silva and Mark Potter)

More News
27 Nov 2023 09:20

LONDON BROKER RATINGS: Peel, Numis up Rightmove; Goldman cuts Entain

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
23 Nov 2023 18:41

IN BRIEF: AstraZeneca Chair Demare buys shares for over GBP200,000

AstraZeneca PLC - Cambridge-based pharmaceutical company - Chair Michel Demare buys 2,000 shares in total on Wednesday and Tuesday. Buys 1,000 shares for GBP101.05 each on Tuesday and 1,000 shares for GBP101.70 each on Thursday, for a total of GBP202,752.

Read more
20 Nov 2023 10:49

AstraZeneca launches new life sciences tech innovation firm Evinova

(Alliance News) - AstraZeneca PLC on Monday launched Evinova, a new health technology business focused on accelerating innovation across the life sciences sector, delivery of clinical trials and better health outcomes.

Read more
17 Nov 2023 15:20

London close: Stocks higher despite weaker retail sales data

(Sharecast News) - London's stock markets finished in a positive state on Friday despite weaker-than-expected UK retail sales figures.

Read more
17 Nov 2023 12:00

LONDON MARKET MIDDAY: Stocks shrug off downbeat UK retail sales

(Alliance News) - Stock prices in London were up at midday on Friday, as a week of favourable data as far as inflation goes gave investors a reason to overlook disappointing UK retail sales figures.

Read more
17 Nov 2023 09:03

LONDON MARKET OPEN: Stocks up despite UK retail sales growth miss

(Alliance News) - Stock prices in London opened higher on Friday, despite weaker-than-expected October retail sales figures for the UK.

Read more
17 Nov 2023 08:31

TOP NEWS: US approves AstraZeneca's Truqap for form of breast cancer

(Alliance News) - AstraZeneca PLC on Friday said that the US Food & Drug Administration approved its drug Truqap in combination with Faslodex to treat patients with an advanced form of breast cancer.

Read more
17 Nov 2023 07:58

LONDON BRIEFING: UK retail sales fall; AstraZeneca gets US approval

(Alliance News) - Stock prices in London are still set to open higher on Friday, despite October retail sales figures for the UK disappointing shortly before the opening bell.

Read more
17 Nov 2023 07:16

AstraZeneca gets US approval for breast cancer treatment

(Sharecast News) - AstraZeneca's 'Truqap', or capivasertib, in combination with 'Faslodex', or fulvestrant, has secured approval from the US Food and Drug Administration (FDA) for specific breast cancer treatments, the company announced on Friday.

Read more
14 Nov 2023 10:51

TOP NEWS: AstraZeneca Imfinzi fails to meet endpoint in cancer trial

(Alliance News) - AstraZeneca PLC on Tuesday said the Pacific-2 phase III trial for Imfinzi as an early treatment lung cancer immunotherapy treatment administered with chemoradiotherapy, did not meet its primary endpoint.

Read more
14 Nov 2023 09:22

AstraZeneca's latest lung cancer trial fails its primary endpoint

(Sharecast News) - AstraZeneca announced on Tuesday that its 'PACIFIC-2' phase three trial for Imfinzi, or durvalumab, concurrently administered with chemoradiotherapy (CRT), did not achieve its primary endpoint of progression-free survival compared to CRT alone.

Read more
13 Nov 2023 09:45

LONDON BROKER RATINGS: Diageo gets price target cuts; JPMorgan ups M&G

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning:

Read more
9 Nov 2023 15:02

London close: Stocks gain as investors await Powell speech

(Sharecast News) - London's stock markets were buoyant at the close of trading on Thursday, influenced by Chinese inflation data, a substantial influx of corporate news, and a speech from the Fed chair later in the global day.

Read more
9 Nov 2023 12:06

LONDON MARKET MIDDAY: FTSE up despite higher for longer US rates fear

(Alliance News) - European equities were on the up on Thursday, despite lingering US interest rate worries and poor China data.

Read more
9 Nov 2023 11:02

Lancashire Holdings declares special dividend after strong year so far

(Alliance News) - Lancashire Holdings Ltd on Thursday said it approved a capital return of up to USD169 million, and it reported rising gross premiums written for the year-to-date.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.